Published by Josh White on 6th December 2024
(Sharecast News) - Syncona announced positive three-month interim results from the phase two 'DAWN' trial conducted by its portfolio company Beacon Therapeutics on Friday.
URL: http://www.digitallook.com/dl/news/story/34739421/...